TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 356237

Group type: EXPERIMENTAL
Intervention: Proquazone (900 mg daily for 3 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg daily for 3 weeks)
Number of subjects: 39
Study: 31987456

Group type: EXPERIMENTAL
Intervention: Off-label recommendations supported by randomized controlled trial (RCT) data
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mechanism-based agents applied in rare cancers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-RCT data showing significant efficacy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recommendations without RCT data
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NCCN recommendations
Number of subjects: 44
Study: 29072830

Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control (no provision of kit)
Number of subjects: 1060
Study: 25760065

Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied once per week until remission of pain (T1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desensitizing gel applied once per week followed immediately by restoration with resin composite (T2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desensitizing gel once per week until remission of pain and then restoration with resin composite (T3)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Restoration with resin composite (T4)
Number of subjects: 17
Study: 23538621

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 22338171

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX) at 10 mg plus low-dose methylprednisolone (MP) at 0.5 mg x kg(‐1) x d(‐1) in Group A
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard-dose methylprednisolone (MP) at 1-2 mg x kg(‐1) x d(‐1) in Group B
Number of subjects: 78
Study: 19570931

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 17705571

Group type: EXPERIMENTAL
Intervention: Manidipine 10-20 mg once daily
Number of subjects: 195

Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 195
Study: 15385735

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/d for 30 days)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 11216728

Group type: EXPERIMENTAL
Intervention: Normothermic (warm) conditions during CABS
Number of subjects: 209

Group type: COMPARATOR
Intervention: Hypothermic (cold) conditions during CABS
Number of subjects: 209
Study: 9300226

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 20
Study: 7936281

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 3612823

Group type: EXPERIMENTAL
Intervention: Barbach's preorgasmic treatment program
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 29244528

Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + Aromatase Inhibitor (AI)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Lapatinib (LAP) + TRAS + AI
Number of subjects: 355
Study: 28479001

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg 3 times a day
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg 3 times a day
Number of subjects: 332

Group type: COMPARATOR
Intervention: Combined AMS incidence
Number of subjects: 332
Study: 26630680

Group type: EXPERIMENTAL
Intervention: 5‐methylenetetrahydrofolate (1 mg daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Folic acid (1 mg daily)
Number of subjects: 220
Study: 24270304

Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 226

Group type: COMPARATOR
Intervention: Printed brochure training
Number of subjects: 226

Group type: COMPARATOR
Intervention: Computer-based training
Number of subjects: 226
Study: 20950507

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs (face-to-face and self-directed packages)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Educational intervention for RCF staff (30-minute blocks, flexible program)
Number of subjects: 342
Study: 18925903

Group type: EXPERIMENTAL
Intervention: CsA/Aza
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tac/MMF
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 17159119

Group type: EXPERIMENTAL
Intervention: Apraxia treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (aphasia) treatment
Number of subjects: 33
Study: 15504842

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/RTV) at 667/100 mg every 12 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Indinavir (IDV) alone at 800 mg every 8 hours
Number of subjects: 27
Study: 11174287

Group type: EXPERIMENTAL
Intervention: Intraluminal administration of peppermint oil (200 mL solution: 8 mL peppermint oil + 0.2 mL Tween 80 per 1 L water with 0.04% indigo carmine)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (solution without peppermint oil)
Number of subjects: 409
Study: 9430090

Group type: EXPERIMENTAL
Intervention: Dietary sitosterol intake increased to 1.8 mg/kg, 2.6 mg/kg, and 3.5 mg/kg/day in the homozygote after a basal low-sitosterol diet (33 mg per 2000 kcal).
Number of subjects: 3

Group type: COMPARATOR
Intervention: Increased dietary sitosterol content (three-fold) while maintaining dietary cholesterol in the homozygous and hypercholesterolemic control.
Number of subjects: 3
Study: 8431334

Group type: EXPERIMENTAL
Intervention: isoflurane in 65% nitrous oxide in oxygen
Number of subjects: 13

Group type: COMPARATOR
Intervention: isoflurane in air and oxygen (FIO2 0.35)
Number of subjects: 13
Study: 3627875

Group type: EXPERIMENTAL
Intervention: Enfamil Premature with 40 mumol/dl of Tau
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enfamil Premature (unsupplemented)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 24
Study: 30264119

Group type: EXPERIMENTAL
Intervention: Algorithm-based therapy (n=255)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Usual practice (n=254)
Number of subjects: 509
Study: 27422898

Group type: EXPERIMENTAL
Intervention: MyPlan1.0. (intervention group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study: 24996550

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 388
Study: 22572889

Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20942269

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine administration (combined with intrathecal bupivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine alone (Control group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Intrathecal bupivacaine alone)
Number of subjects: 50
Study: 19026303

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study: 16140027

Group type: EXPERIMENTAL
Intervention: Inhaled bimosiamose 70 mg bid on days 1-3 and 70 mg once on the morning of day 4
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14594033

Group type: EXPERIMENTAL
Intervention: HDBR exercise group (exercise with a bicycle ergometer in the supine position, 1 hour/day during bed rest)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HDBR control group (no exercise)
Number of subjects: 10
Study: 10444051

Group type: EXPERIMENTAL
Intervention: High oxygen transmissibility (Dk/L) RGP lenses for 12 months of extended wear
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: High Dk lenses fitting strategy
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Younger patients with greater corneal curvature (K) and less predicted residual astigmatism
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Reasons for failure to adapt to RGP daily wear
Number of subjects: 411
Study: 8526631

Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 685

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 685
Study: 2801572

Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5, 5.0, and 10.0 mg intravenous
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicardipine after atenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atenolol followed by placebo
Number of subjects: 8
Study: 4271320

Group type: EXPERIMENTAL
Intervention: Chemotherapy with immunotherapy (multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G.)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 107
Study: 31754882

Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30425011

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice packs applied covering the operative forearm for 120 minutes after wound closure)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 85
Study: 28287476

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 409 mg total (poly)phenols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 787 mg total (poly)phenols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1238 mg total (poly)phenols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1534 mg total (poly)phenols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1910 mg total (poly)phenols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice (all doses)
Number of subjects: 10
Study: 25249405

Group type: EXPERIMENTAL
Intervention: Weight, waist or hip circumferences, insulin levels, high triglycerides (TG), low high-density lipoprotein (HDL)
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Fasting blood sugar (FBS)
Number of subjects: 859
Study: 23711600

Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus intra- and postoperative ketamine and clonidine premedication (MCK)
Number of subjects: 49

Group type: COMPARATOR
Intervention: IV-PCA morphine alone (M)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus oral clonidine premedication (MC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus intra- and postoperative ketamine (MK)
Number of subjects: 49
Study: 21263343

Group type: EXPERIMENTAL
Intervention: Low-glycemic nutritional fitness program for 12 weeks
Number of subjects: 75
Study: 19572992

Group type: EXPERIMENTAL
Intervention: Parenteral ampicillin (P‐Ab)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (O‐Ab)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: No antibiotic (N‐Ab)
Number of subjects: 294
Study: 16680103

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% ointment
Number of subjects: 25
Study: 15170279

Group type: EXPERIMENTAL
Intervention: CT scan referral
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no CT scan)
Number of subjects: 189
Study: 11479164

Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (DHD)
Number of subjects: 12
Study: 9487789

Group type: EXPERIMENTAL
Intervention: Female expert testimony presented prior to defendant's testimony
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female expert testimony
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert testimony presented early
Number of subjects: 0
Study: 8001208

Group type: EXPERIMENTAL
Intervention: mivacurium 0.15 mg.kg‐1 as a single bolus dose
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: mivacurium 0.015 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1 as a single bolus dose
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: mivacurium 0.015 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: succinylcholine 1.0 mg.kg‐1
Number of subjects: 70
Study: 3511419

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin
Number of subjects: 98
Study: 30396674

Group type: EXPERIMENTAL
Intervention: Virtual monochromatic imaging (VMI) at 40, 50, and 60 keV
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Virtual monochromatic imaging (VMI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional 120 kVp images
Number of subjects: 35
Study: 27936879

Group type: EXPERIMENTAL
Intervention: Cryosclerosis
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 96
Study: 25876346

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture and EEG biofeedback therapy (combined therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: EEG biofeedback therapy (control group)
Number of subjects: 100
Study: 21750460

Group type: EXPERIMENTAL
Intervention: Botox injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lidocaine/Depomedrol injection
Number of subjects: 14
Study: 20010618

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 160/12.5 mg (V/HCTZ)
Number of subjects: 648

Group type: COMPARATOR
Intervention: valsartan 80 mg (V-low)
Number of subjects: 648

Group type: COMPARATOR
Intervention: valsartan 160 mg (V-high)
Number of subjects: 648
Study: 19186332

Group type: EXPERIMENTAL
Intervention: Dance Dance Revolution (DDR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DDR
Number of subjects: 60
Study: 18435564

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 15239261

Group type: EXPERIMENTAL
Intervention: Carboplatin-lipiodol emulsion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Doxorubicin-lipiodol emulsion
Number of subjects: 65
Study: 11739221

Group type: EXPERIMENTAL
Intervention: Clinical medication review by a pharmacist
Number of subjects: 1188

Group type: COMPARATOR
Intervention: Normal general practice review
Number of subjects: 1188
Study: 9240887

Group type: COMPARATOR
Intervention: Gastrin levels before NEC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Gastrin levels after NEC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neurotensin levels after NEC
Number of subjects: 14

Group type: COMPARATOR
Intervention: VIP values before NEC
Number of subjects: 14

Group type: COMPARATOR
Intervention: VIP values after NEC
Number of subjects: 14
Study: 8318484

Group type: EXPERIMENTAL
Intervention: 5 microliters microdrops of cyclopentolate 0.5% and phenylephrine 2.5%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard 26 microliters eye drops of cyclopentolate 0.5% and phenylephrine 2.5%
Number of subjects: 26
Study: 3704898

Group type: EXPERIMENTAL
Intervention: Subcutaneous drains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stay suture closure
Number of subjects: 0
Study: 31529406

Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atacicept (all doses)
Number of subjects: 24
Study: 30481790

Group type: EXPERIMENTAL
Intervention: Ophthalmic insert Mydriasert®
Number of subjects: 80

Group type: COMPARATOR
Intervention: Eye drops (2.5% phenylephrine and 0.5% tropicamide)
Number of subjects: 80
Study: 26094972

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 /0.077% NaF dentifrice
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.32% NaF/0.3% triclosan dentifrice
Number of subjects: 36
Study: 24972663

Group type: EXPERIMENTAL
Intervention: Problem Based Method groups (PBM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 50
Study: 24437167

Group type: EXPERIMENTAL
Intervention: Sublingual dose of nitrates (nitroglycerin and mononitrate isosorbide)
Number of subjects: 41
Study: 21500886

Group type: EXPERIMENTAL
Intervention: 2-session group coping skills intervention targeting personality risk factors
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control no-intervention condition
Number of subjects: 364
Study: 19633827

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatment with perindopril-indapamide (n = 623)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intensive glucose control targeting HbA(1c) of < or = 6.5% (n = 630)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo (n = 618)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Standard glucose control (n = 611)
Number of subjects: 1602
Study: 17086852

Group type: EXPERIMENTAL
Intervention: Repositioning appliance (REPOS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-repositioning appliance (NONREPOS)
Number of subjects: 33
Study: 15582060

Group type: EXPERIMENTAL
Intervention: Money to households
Number of subjects: 5600

Group type: COMPARATOR
Intervention: Resources to local health teams
Number of subjects: 5600

Group type: EXPERIMENTAL
Intervention: Both packages
Number of subjects: 5600

Group type: COMPARATOR
Intervention: Neither
Number of subjects: 5600
Study: 11303848

Group type: EXPERIMENTAL
Intervention: Cefepime 50 mg/kg/dose administered every 8 to 12 hours
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 259

Group type: COMPARATOR
Intervention: Ceftazidime, Cefotaxime, Cefuroxime (comparator therapy)
Number of subjects: 259
Study: 8990415

Group type: EXPERIMENTAL
Intervention: Low-fat diet ad libitum
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Moderate, unsupervised exercise
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (maintained weight)
Number of subjects: 58
Study: 8491068

Group type: EXPERIMENTAL
Intervention: Remikiren (intravenous) at doses of 10, 20, 40, 80, 160, and 320 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Remikiren (oral) at doses of 100, 200, 400, 800, and 1600 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Remikiren (oral) at 1600 mg
Number of subjects: 9
Study: 3329766

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) 655 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetyl salicylic acid (ASA) 652 mg
Number of subjects: 12
Study: 30074156

Group type: EXPERIMENTAL
Intervention: New nano-film single-rivet occluders
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional occluders (Control)
Number of subjects: 23
Study: 26684923

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose buprenorphine (initial dosage 0.1 mg once or twice daily; mean final dosage 0.44 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24441865

Group type: EXPERIMENTAL
Intervention: Once-daily dosing (OD) of amikacin (15 or 20 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Twice-daily dosing (TD) of amikacin (15 or 20 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amikacin pharmacokinetics
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amikacin dosing based on neonatal age
Number of subjects: 31
Study: 22251022

Group type: EXPERIMENTAL
Intervention: Switch to different SSRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switch to an alternate antidepressant (venlafaxine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switch to an alternate SSRI plus cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine plus CBT
Number of subjects: 0
Study: 20016124

Group type: EXPERIMENTAL
Intervention: Metacognitive training (self-testing strategy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 56
Study: 18534618

Group type: EXPERIMENTAL
Intervention: Inhaled CO2 (0.8%) for 2 hours
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Theophylline for 2 hours
Number of subjects: 42

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 42
Study: 15668285

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Objective tumor response
Number of subjects: 75
Study: 11868796

Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10907738

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 0
Study: 7785682

Group type: EXPERIMENTAL
Intervention: Topical 0.125% verapamil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical 0.25% verapamil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study: 2366025

Group type: EXPERIMENTAL
Intervention: M.R.I. (Magnetic Resonance Imaging)
Number of subjects: 9